Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Determination of candidate genes involved in schizophrenia using the whole-exome sequencing.

Senormanci O, Karakas Celik S, Valipour E, Dogan V, Senormanci G.

Bratisl Lek Listy. 2018;119(9):572-576. doi: 10.4149/BLL_2018_104.

PMID:
30226068
2.

The neurosteroidogenic enzyme 5α-reductase modulates the role of D1 dopamine receptors in rat sensorimotor gating.

Frau R, Mosher LJ, Bini V, Pillolla G, Pes R, Saba P, Fanni S, Devoto P, Bortolato M.

Psychoneuroendocrinology. 2016 Jan;63:59-67. doi: 10.1016/j.psyneuen.2015.09.014. Epub 2015 Sep 24.

3.

Targeting neurosteroid synthesis as a therapy for schizophrenia-related alterations induced by early psychosocial stress.

Frau R, Abbiati F, Bini V, Casti A, Caruso D, Devoto P, Bortolato M.

Schizophr Res. 2015 Nov;168(3):640-8. doi: 10.1016/j.schres.2015.04.044. Epub 2015 May 18.

4.

Steroid 5α-reductase as a novel therapeutic target for schizophrenia and other neuropsychiatric disorders.

Paba S, Frau R, Godar SC, Devoto P, Marrosu F, Bortolato M.

Curr Pharm Des. 2011;17(2):151-67. Review.

PMID:
21361868
5.

SRD5A2 is associated with increased cortisol metabolism in schizophrenia spectrum disorders.

Steen NE, Tesli M, Kähler AK, Methlie P, Hope S, Barrett EA, Larsson S, Mork E, Løvås K, Røssberg JI, Agartz I, Melle I, Djurovic S, Lorentzen S, Berg JP, Andreassen OA.

Prog Neuropsychopharmacol Biol Psychiatry. 2010 Dec 1;34(8):1500-6. doi: 10.1016/j.pnpbp.2010.08.013. Epub 2010 Aug 25.

PMID:
20800085
6.

Antipsychotic-like properties of 5-alpha-reductase inhibitors.

Bortolato M, Frau R, Orrù M, Bourov Y, Marrosu F, Mereu G, Devoto P, Gessa GL.

Neuropsychopharmacology. 2008 Dec;33(13):3146-56. doi: 10.1038/npp.2008.39. Epub 2008 Mar 19.

Supplemental Content

Loading ...
Support Center